BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Pfenex Inc. Announces Strategic Agreement with SAFC


6/7/2011 10:33:31 AM

San Diego, California June 7, 2011 – Pfenex Inc., an industry leader in protein expression through the Pfenex Expression Technology™ platform, announced today that it has entered into a non-exclusive strategic partnership with SAFC®, a unit of the Sigma-Aldrich Corporation (NASDAQ:SIAL) and a global leader in biopharmaceutical contract manufacturing. Under the agreement, Pfenex Inc. will engineer production strains and processes for SAFC’s contract manufacturing customers, and the developed processes will ultimately be transferred to SAFC’s recently expanded fermentation facility in Jerusalem, Israel for cGMP production.

In addition, the companies plan to work together to combine Pfenex’s Reagent Proteins product offerings in the area of vaccine components with SAFC’s expertise and facilities for bioconjugation to support development of conjugate vaccines.

This collaboration is expected to provide SAFC and the biotechnology community with access to an industry-leading expression platform, a comprehensive range of vaccine carrier proteins, and enable preclinical and clinical development to progress much more quickly and efficiently.

“Our partnership agreement with SAFC combines a cutting edge expression technology and a broad offering of vaccine components with a world class contract manufacturing services provider, facilitating the speed and reliability with which important new drugs can be brought to patients.” said Dr Bertrand Liang, CEO of Pfenex Inc.

“Providing our customers access to Pfenex’s expression system is a valuable addition to our complex technology portfolio,” said Mark Cassidy, Vice President of SAFC’s Contract Manufacturing Services. “This alliance reinforces SAFC’s commitment to bringing our customers the latest technological solutions in the advancement of biopharmaceutical manufacturing.”

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com

About Reagent Proteins

Reagent Proteins is a leading supplier of reagent, pre-clinical and cGMP grade proteins to the biopharmaceutical and vaccine development community. We ensure that scientists have ready access to a comprehensive offering of high quality proteins to enable their development efforts to proceed efficiently. For more information please visit www.reagentproteins.com

SAFC and Sigma-Aldrich are registered trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

Pfenex Contact:

Cassidy Brady

Marketing Manager

858-344-7207

cbrady@pfenex.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES